Tsavellas G, Huang A, McCullough T, Patel H, Araia R, Allen-Mersh T G
Division of Surgery, Faculty of Medicine, Imperial College School of Science, Technology and Medicine, Chelsea & Westminster Hospital, London, UK.
Clin Exp Metastasis. 2002;19(6):495-502. doi: 10.1023/a:1020350117292.
The aim of this study was to determine whether flow cytometry (FACS) could detect spiked or circulating colorectal cancer cells. A flow cytometric assay was developed and its sensitivity compared with the reverse transcription polymerase-chain reaction (RT-PCR), using carcinoembryonic antigen (CEA) and cytokeratin (CK) 20 mRNA as target markers. Sensitivity limits for RT-PCR and flow cytometry (FACS) were established using spiked blood, and pre-operative blood samples from 20 colorectal cancer patients and 16 healthy no-cancer controls were analysed for circulating tumour cells (CTC) using both methods. Blood samples for FACS analysis were immuno-magnetically enriched using ferrofluid particles. CTC were defined as positive for pan-cytokeratin and negative for CD45 pan-leucocyte antigen (CK+/CD45- events). There was a significant (P < 0.0001) correlation between the number of spiked cancer cells and their recovery using FACS. The lowest detectable concentration was 20 spiked cancer cells in 14 ml blood for both RT-PCR and FACS. A positive FACS result significantly (P < 0.05) concurred with a positive RT-PCR result in spiked blood. The number of CK+/CD45- events detected in the blood of colorectal cancer patients was not significantly greater (P = 0.07) than in blood taken from 'no cancer' controls and furthermore there was no concordance (P = 1) between RT-PCR and FACS positivity in cancer patients' blood. FACS detection of tumour cells was feasible in vitro, and correlated with RT-PCR. However, its sensitivity in vivo was poor and did not correlate with RT-PCR detection of CTC. Uncertainties about antigen expression on normal circulating cells and about CTC phenotype need to be resolved, before FACS can be developed for detection of tumour cells within the circulation.
本研究的目的是确定流式细胞术(FACS)能否检测到掺入的或循环中的结肠癌细胞。开发了一种流式细胞术检测方法,并将其灵敏度与逆转录聚合酶链反应(RT-PCR)进行比较,使用癌胚抗原(CEA)和细胞角蛋白(CK)20 mRNA作为靶标标志物。使用掺入癌细胞的血液确定RT-PCR和流式细胞术(FACS)的灵敏度极限,并使用这两种方法对20例结肠癌患者和16例健康非癌症对照的术前血液样本进行循环肿瘤细胞(CTC)分析。用于FACS分析的血液样本使用铁磁流体颗粒进行免疫磁富集。CTC被定义为全细胞角蛋白阳性且CD45全白细胞抗原阴性(CK+/CD45-事件)。掺入的癌细胞数量与其通过FACS回收之间存在显著相关性(P < 0.0001)。RT-PCR和FACS在14 ml血液中可检测到的最低癌细胞浓度均为20个。在掺入癌细胞的血液中,FACS阳性结果与RT-PCR阳性结果显著一致(P < 0.05)。在结肠癌患者血液中检测到的CK+/CD45-事件数量并不显著多于(P = 0.07)“无癌症”对照血液中的数量,此外,癌症患者血液中RT-PCR和FACS阳性之间不存在一致性(P = 1)。FACS在体外检测肿瘤细胞是可行的,并且与RT-PCR相关。然而,其在体内的灵敏度较差,且与CTC的RT-PCR检测不相关。在将FACS开发用于检测循环中的肿瘤细胞之前,需要解决正常循环细胞上抗原表达以及CTC表型的不确定性问题。